trending Market Intelligence /marketintelligence/en/news-insights/trending/zhktucewl8JkNYH_t_2oRg2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Synlogic COO to step down

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Synlogic COO to step down

Synlogic Inc. said COO and head of corporate development, Andrew Gengos, will leave the company on Jan. 15, 2019.

The company, which agreed to a severance package with Gengos, said in a news release that his employment was "terminated without cause as a result of his role at the company being materially diminished."

Cambridge, Mass.-based Synlogic is a clinical-stage biopharmaceutical company that focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory and cancer diseases.